Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Bad Nenndorf – page 30

792 clinical trials in Bad Nenndorf, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Bad Nenndorf at a glance
792
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

792 trials in Bad Nenndorf

Open in trial search

Acute myeloid leukaemia

Not yet recruiting

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using CPX-351, Gemtuzumab Ozogamicin, and a Drug Combination

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:GPOH gGmbH

Cystic fibrosis

Not yet recruiting

Study on the Effects of Dirocaftor, Posenacaftor, and Nesolicaftor for Adults with Cystic Fibrosis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dirocaftor
  • Sponsor:Universitair Medisch Centrum Utrecht

Colitis ulcerative

Not yet recruiting

Study on the Effects of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Colitis ulcerative

Not yet recruiting

Study on the Effectiveness of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Cholangiocarcinoma

Not yet recruiting

Study of Ivosidenib for Patients with Previously Treated Advanced or Metastatic Cholangiocarcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ivosidenib
  • Sponsor:Servier Affaires Medicales

Malignant melanoma

Not yet recruiting

Study Comparing MK-7684A (Vibostolimab and Pembrolizumab) with Pembrolizumab for Adults and Children with High-Risk Melanoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

HIV infection

Not yet recruiting

Study on Switching HIV Treatment to Doravirine and Islatravir for Patients with HIV-1

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bictegravir
  • Sponsor:Merck Sharp & Dohme LLC

HIV infection

Not yet recruiting

Study on Doravirine and Islatravir for People with HIV-1 Previously Treated with the Same Drug Combination

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Doravirine
  • Sponsor:Merck Sharp & Dohme LLC

Ischaemic stroke

Not yet recruiting

Study on Redasemtide for Adults with Acute Ischemic Stroke Not Eligible for Standard Treatments

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Redasemtide
  • Sponsor:Shionogi B.V.

Biliary tract disorder

Not yet recruiting

Study on Durvalumab with Chemotherapy for Patients with Advanced Biliary Tract Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Colitis ulcerative

Not recruiting

Evaluation of Long-Term Efficacy and Safety of Obefazimod as Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Crohn's disease

Not recruiting

Study on the Effectiveness and Safety of Guselkumab and Ustekinumab for Patients with Moderate to Severe Crohn's Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Bad Nenndorf

What the registry says about research in the country

01 Cardiovascular Diseases

Researchers in Bad Nenndorf are evaluating how a novel oral agent elecoglipron influences the progression of chronic kidney disease in adult participants, with all patients receiving background therapy with the SGLT2i dapagliflozin. The studies aim to reduce the risk of a sustained ≥50% decline in kidney function, end‑stage kidney disease, or death.

  • Renal outcomes linked to cardiovascular risk
  • Impact of SGLT2 inhibitor background therapy
  • Monitoring of eGFR decline and albuminuria levels
  • Composite endpoint of kidney failure and all‑cause mortality

Both trials are actively recruiting at two local sites, offering patients the opportunity to contribute to advancing therapies that bridge heart and kidney health.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.